Xenon Pharmaceuticals (XENE) Retained Earnings (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Retained Earnings data on file, last reported at -$1.2 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 44.86% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$1.2 million, a 44.86% decrease from a year earlier, with the FY2025 full-year figure at $335000.0, up 100.04% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.2 million, down from $335000.0 in the prior quarter.
• Over the last five years, Retained Earnings for XENE reached as high as $335000.0 in Q4 2025 and fell as low as -$1.1 billion in Q3 2025.
• Historically, Retained Earnings has averaged -$461.0 million across 5 years, with a median of -$482.7 million in 2022.
• Across the five-year window, Retained Earnings plunged 48662.32% in 2022 and soared 100.04% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$482.7 million in 2022, then slumped by 37.78% to -$665.1 million in 2023, then plunged by 35.23% to -$899.5 million in 2024, then surged by 100.04% to $335000.0 in 2025, then plunged by 461.49% to -$1.2 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$1.2 million in Q1 2026, $335000.0 in Q4 2025, and -$1.1 billion in Q3 2025.